MDS and CMML
Haematology · 2021–2021
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| decitabine with cedazuridine Treatment of myelodysplastic syndrome (MDS) intermediate-2 or high-risk according to the International Prognostic Scoring System (IPSS) and chronic… | Jul 2021 | Recommended with restriction | input received Leukaemia Foundation |
Who spoke
Leukaemia Foundation
What the PBS pays
$12M in government benefit over 2024–25, across 2,478 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| decitabine with cedazuridine | $11.7M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.